In this study, we explored the utility of changes in serum C-reactive protein (CRP) levels as a potential on-treatment surrogate of OS in two randomized clinical trials of atezolizumab (anti-PD-L1) monotherapy in second-line non-small cell lung cancer (NSCLC) [10, 11]. This evidence concerns the gene CRP and non-small cell lung carcinoma.